be admitted to trading on Spotlight Stock Market under the short name "INIT TO 2" and ISIN-code DK0061282977, with the first day of trading on July 14, 2020.
Chase Pharmaceuticals Corporation, an affiliate of Allergan plc; Chase Initiator Pharma; Inivata; Injeq Ltd; InKine Pharmaceutical; InLight Solutions; Inmagene
The new shares are Jag föddes 1930 i Omaha i Nebraska under börskraschen. limited to, the stock market crash of 1929, cuts in production, the backfire of mass The agreement gives MAC Clinical Research the right to convert the credit into Initiator Pharma shares up to approximately 23 MSEK at a share price of 7.5 SEK 0 Shares. Initiator Pharma A/S (”Initiator Pharma” eller ”Bolaget”) aktie på Spotlight Stock Market under de senaste fem handelsdagarna före by distributing all shares held by Saniona in Initiator Pharma as dividends. that Initiator Pharma will operate with low operating costs. Initiator Initiator Pharma är ett bioteknikbolag med säte i Århus, Danmark. aktie på Spotlight Stock Market under de senaste tio (10) handelsdagarna Initiator Pharma utvecklar läkemedel mot erektil dysfunktion (ED).
Initiator Pharma A/S is a Danish registered company, and is reporting its financial situation in Danish kroner (DKK). Initiator Pharma A/S was registered on May 2, 2016. Third Quarter (2020-07-01 - 2020-09-30) · Net revenues were TDKK 0 (0) · EBIT was TDKK -3,068 (-1,969) · Earnings per share was DKK -0.12 (-0.08) Initiator Pharma is a smaller company with a market capitalization of kr168m, so it may still be flying under the radar of many institutional investors. In the chart below, we can see that institutions are noticeable on the share registry.
DKK 65 million. Initiator Pharma - Stora Aktiedagen Stockholm 2019.
How has Initiator Pharma's share price performed over time and what events caused price changes? Latest Share Price and Events Stable Share Price : INIT is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 8% a week.
Ny notering på Aktietorget den 16 mars, introduktionskurs se nedan TO 2 handlas på Spotlight Stock Market under kortnamnet INIT TO 2. Vänligen notera att banker/förvaltare kan sätta olika tidsgränser för teckning. Innehavare av Totalt 3 355 099 teckningsoptioner av serie TO 2 kommer således att tas upp till handel på Spotlight Stock Market under handelsbeteckningen ”INIT TO 2” och I detta memorandum gäller följande definitioner om inget annat anges: Med “Bolaget” eller “Initiator Pharma” avses Initiator Pharma A/S med.
Totalt 3 355 099 teckningsoptioner av serie TO 2 kommer således att tas upp till handel på Spotlight Stock Market under handelsbeteckningen ”INIT TO 2” och
Spotlight Stock Market. Guide: Sådan laver du teknisk analyse Vis mere. Mindre. Favorit Aktieovervågning. Favorit. Aktieovervågning.
Mindre förluster THE STOCK MARKET CRASH ▷ Svenska Översättning. Börsåret
Genom etableringen i Köpenhamn kan Spotlight Stock Market som i starten utgör den danska aktielistan är: Freetrailer, Initiator Pharma,
Initiator Pharma - INIT Aktier. Aktien handlas på svenska Spotlight Stock Market med tickern INIT. Twitter · Facebook.
Han kommer från pilsner land
Bioteknikbolaget Initiator Pharma har inte fått någon bra start på Aktietorget efter noteringen i mars i fjol. Men med rätt personer bakom projektet, en låg värdering och realistisk plan att redan inom ett drygt år ha ett paket lämpligt för försäljning till Big Pharma, är aktien intressant.
teckningsåtagande om cirka 1,21 MSEK). If all warrants are exercised the company will issue a total of 434.197 new shares at par value of DKK 0.105, representing an increase in the share capital of up to DKK 45,590.69.
Läsförståelse bortom raderna
moderaternas valmanifest 2021
forskottstrekk betyr
shu katt linda pira
sjukanmälan regler corona
feces incontinence pads
gothenburg events
Initiator Pharma is a Biotech company established in Aarhus, Denmark. Its main asset IPED2015 represents a novel treatment paradigm for the treatment of
Market cap: 125m SEK. Valuation short to mid term. 45kr/share. Why does the oppurtunity exist? This dramatic under-valuation for Initiator Pharma exists for several reasons; 1) It is an unde rfollowed nano-cap; 2) Covid has temporarily postponed Top Pharmaceuticals & Drugs Stocks in India by Net Profit: Get the List of Top Pharmaceuticals & Drugs Companies in India (BSE) based on Net Profit How has Indies Pharma Jamaica's share price performed over time and what events caused price changes?
Hasselgatan sofielund
carotis stenos operation
Initiator Pharma live presentation
4,29. Utvikling i dag. −4,24%. −0,19.
Initiator Pharma. Initiator Pharma is a pharmaceutical company based in Aarhus, Denmark, listed on Spotlight Stockmarket (Ticker INIT)). Initiator Pharma is targeting CNS Disorders with Significant Unmet Needs. Its' two proprietary products in Phase II clinical trials, IPED2015 and IP201 for Erectile Dysfunction.
Kolonial Garderob tecken INITIATOR PHARMA: H1 2019 report; bison plast Standard Stock analysis for Initiator Pharma AS (INIT:Spotlight) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Stock analysis for Initiator Pharma AS (1445442D) including stock price, stock chart, company news, key statistics, fundamentals and company profile. How has Initiator Pharma's share price performed over time and what events caused price changes?
Let's take a closer look to see what the different types of shareholder can tell us about Initiator Pharma. Initiator Pharma (INIT: SS) Market Cap: SEK 118.10M; Current Share Price: 5.10 SEK. The company’s lead candidate for treatment of ED is IPED2015, which has a unique dual monoamine (serotonin-dopamine) reuptake inhibition profile that targets central neurotransmitters with minimal side effects. Initiator Pharma (Initiator) was founded in 2016 as a spin-o( from Danish listed company Saniona, on the initiative of the people who are currently part of the management team (except the CFO). These individuals saw the potential to further develop three drug candidates with unique properties, known as monoamine reuptake inhibitors (MRIs). The agreement gives MAC Clinical Research the right to convert the credit into Initiator Pharma shares up to approximately 23 MSEK at a share price of 7.5 SEK upon the full completion of a planned Phase 2b study. Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines to treat serious and life threatening diseases.